AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$65.04
neg -0.06
-0.09%
Today's Range: 65.02 - 65.92 | ABBV Avg Daily Volume: 6,130,400
Last Update: 04/26/17 - 4:02 PM EDT
Volume: 4,982,087
YTD Performance: 3.96%
Open: $65.19
Previous Close: $65.10
52 Week Range: $55.06 - $68.12
Oustanding Shares: 1,593,576,738
Market Cap: 103,040,671,879
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 1 1 1 1
Hold 9 9 8 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 1 1
Mean Rec. 2.36 2.36 2.50 2.50
Latest Dividend: 0.64
Latest Dividend Yield: 3.96%
Dividend Ex-Date: 04/11/17
Price Earnings Ratio: 13.41
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
13.41 17.80 30.50
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
6.06% 6.77% 32.48%
GROWTH 12 Mo 3 Yr CAGR
Revenue 14.50 0.40 0.11
Net Income 15.70 0.40 0.13
EPS 15.50 0.40 0.12
Earnings for ABBV:
EBITDA 9.38B
Revenue 25.64B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $1.26 $1.38 $5.50 $6.52
Number of Analysts 9 7 11 10
High Estimate $1.31 $1.42 $5.53 $7.04
Low Estimate $1.24 $1.34 $5.47 $6.24
Prior Year $1.15 $1.26 $4.82 $5.50
Growth Rate (Year over Year) 9.76% 9.18% 14.13% 18.49%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Biotech investors should keep a close eye on the progress in this huge potential market.

2 Biotech Pullback Targets Real Money Pro($)

Acadia and Neurocrine both have catalysts for growth; buy any weakness.
It's pretty normal to have profit-taking after such a strong first quarter.
Bullish
Mar 10, 2017 | 6:51 AM EST
ABBV was placed on the Conviction Buy list, according to Goldman Sachs. $80 price target. Company is growing faster than its peers, but...
Icahn may have a tough time finding interest in this behemoth.
You might want to review your holdings in the sector.
Would get drugs to market faster and possibly more cheaply.

Novice Trade: AbbVie Real Money Pro($)

Getting FDA to streamline its approval process would boost drug makers.
Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.
Value stocks will extend their outperformance over growth stocks that began last year.

Columnist Conversations

View Chart »  View in New Window » XLY has met multiple upside targets, you may want to trail ...
WYN is ripping following this morning's earnings report. The lodging company is up over 8% and is in the numbe...
with the market getting a bit frothy here, we'll add some put protection. this is 2X normal size BOUGHT SPY...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.